Pioglitazone Improves Aortic Wall Elasticity in a Rat Model of Elastocalcinotic Arteriosclerosis
- 1 August 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 46 (2), 372-379
- https://doi.org/10.1161/01.hyp.0000171472.24422.33
Abstract
Specific treatment of age-related aortic wall arteriosclerosis and stiffening is lacking. Because ligands for peroxisome proliferator-activated receptor γ have beneficial effects on the arterial wall in atherosclerosis, via an antiinflammatory mechanism, we investigated whether long-term pioglitazone (Pio) treatment protects against another form of vascular wall disease, arteriosclerosis. We evaluated, in a rat model of elastocalcinotic arteriosclerosis (hypervitaminosis D and nicotine [VDN]), whether Pio (3 mg · kg −1 per day for 1.5 month PO) attenuated arteriosclerosis and its consequences: aortic wall rigidity, increased aortic pulse pressure, and left ventricular hypertrophy. In VDN rats, medial calcification was associated with monocyte/macrophage infiltration and induction of tumor necrosis factor α and interleukin 1β. Pio increased nuclear peroxisome proliferator-activated receptor γ immunostaining in the aortic wall, decreased tumor necrosis factor α ( P − ), tended to decrease interleukin 1β mRNA expression ( P =0.08 versus VDN Pio − ), blunted aortic wall calcification (271±69, P − 562±87 μmol · g −1 dry weight) and prevented fragmentation of elastic fibers (segments per 10 000 μm 2 : 8.4±0.3; P − 10.5±0.6). Pio reduced aortic wall stiffness (elastic modulus/wall stress: 4.8±0.6; P − 10.0±1.6), aortic pulse pressure (30±2 mm Hg; P − 39±4) and left ventricular hypertrophy (1.58±0.05 g · kg −1 ; P − 1.76±0.06). In conclusion, long-term Pio treatment attenuates aortic wall elastocalcinosis and, thus, lowers aortic wall stiffness, aortic pulse pressure, and left ventricular hypertrophy.Keywords
This publication has 15 references indexed in Scilit:
- Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis?Expert Opinion on Investigational Drugs, 2004
- Clinical interest of PPARs ligandsDiabetes & Metabolism, 2004
- Antiinflammatory and antiarteriosclerotic effects of pioglitazone.Hypertension, 2002
- SB 242784, a Selective Inhibitor of the Osteoclastic V-H + -ATPase, Inhibits Arterial Calcification in the RatCirculation Research, 2002
- The role of PPARs in atherosclerosisTrends in Molecular Medicine, 2002
- p27Kip1is an inducer of intestinal epithelial cell differentiationAmerican Journal of Physiology-Cell Physiology, 2000
- Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient miceJCI Insight, 2000
- Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro1Endocrinology, 1999
- Expression of the Peroxisome Proliferator-Activated Receptor (PPAR) in the Mouse Colonic MucosaBiochemical and Biophysical Research Communications, 1996
- Cardiovascular Protection by Calcium AntagonistsPublished by Springer Science and Business Media LLC ,1985